RGM Capital LLC Buys 169,200 Shares of Revvity Inc. $RVTY

Key Points

• RGM Capital LLC increased its holdings in Revvity Inc. by 12.8% in the first quarter, now owning 1,489,791 shares valued at approximately $157.6 million, making it the firm's 6th largest holding.
• Revvity recently declared a $0.07 quarterly dividend to be paid on November 7th, representing an annual yield of 0.3% and a dividend payout ratio of 11.86%.
• The firm's recent earnings report showed earnings per share of $1.18, surpassing estimates and highlighting a 4.1% revenue increase year-over-year, with FY 2025 guidance set between 4.850-4.950 EPS.

RGM Capital LLC raised its holdings in Revvity Inc. (NYSE:RVTY - Free Report) by 12.8% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,489,791 shares of the company's stock after buying an additional 169,200 shares during the period. Revvity makes up approximately 6.5% of RGM Capital LLC's portfolio, making the stock its 6th largest position. RGM Capital LLC owned 1.26% of Revvity worth $157,620,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of RVTY. Raymond James Financial Inc. purchased a new position in Revvity in the fourth quarter valued at $2,248,000. Mariner LLC raised its position in Revvity by 9.8% in the 4th quarter. Mariner LLC now owns 7,746 shares of the company's stock valued at $865,000 after purchasing an additional 689 shares in the last quarter. Marshall Wace LLP boosted its stake in shares of Revvity by 4.6% in the 4th quarter. Marshall Wace LLP now owns 3,556 shares of the company's stock valued at $397,000 after buying an additional 156 shares during the period. OneDigital Investment Advisors LLC purchased a new position in shares of Revvity in the 4th quarter valued at about $220,000. Finally, Coldstream Capital Management Inc. grew its position in shares of Revvity by 6.4% during the fourth quarter. Coldstream Capital Management Inc. now owns 2,390 shares of the company's stock worth $267,000 after buying an additional 143 shares in the last quarter. Hedge funds and other institutional investors own 86.65% of the company's stock.

Revvity Stock Performance

Shares of Revvity stock traded up $0.74 during trading on Thursday, reaching $89.33. The company's stock had a trading volume of 790,390 shares, compared to its average volume of 1,168,118. The company has a 50-day moving average price of $94.21 and a two-hundred day moving average price of $98.26. Revvity Inc. has a fifty-two week low of $85.12 and a fifty-two week high of $129.50. The firm has a market cap of $10.37 billion, a PE ratio of 37.85, a P/E/G ratio of 2.38 and a beta of 0.91. The company has a current ratio of 3.33, a quick ratio of 2.75 and a debt-to-equity ratio of 0.43.

Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings results on Monday, July 28th. The company reported $1.18 earnings per share for the quarter, topping analysts' consensus estimates of $1.14 by $0.04. The firm had revenue of $720.28 million during the quarter, compared to analysts' expectations of $711.26 million. Revvity had a net margin of 10.19% and a return on equity of 7.66%. Revvity's quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.22 EPS. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. On average, analysts forecast that Revvity Inc. will post 4.94 EPS for the current year.

Revvity Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 17th will be issued a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, October 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.3%. Revvity's dividend payout ratio (DPR) is currently 11.86%.

Analyst Ratings Changes

RVTY has been the topic of several analyst reports. Raymond James Financial reaffirmed an "outperform" rating and issued a $115.00 target price (down previously from $120.00) on shares of Revvity in a report on Tuesday, July 29th. Wall Street Zen lowered shares of Revvity from a "buy" rating to a "hold" rating in a report on Sunday, August 3rd. Stifel Nicolaus decreased their price objective on shares of Revvity from $120.00 to $110.00 and set a "hold" rating for the company in a research report on Tuesday, July 29th. UBS Group upgraded shares of Revvity from a "neutral" rating to a "buy" rating and lowered their target price for the stock from $145.00 to $115.00 in a research note on Thursday, May 1st. Finally, Evercore ISI cut their price target on Revvity from $116.00 to $115.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Ten equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $120.07.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.